Prolactinoma drug doses face off: which is better for your metabolism?

NCT ID NCT07045935

Recruiting now Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how different doses of the drug cabergoline affect blood sugar control in people with prolactinoma, a type of pituitary tumor. Researchers will randomly assign 60 adults to different treatment strategies and measure their glucose levels after a sugar drink. The goal is to find the best dose to manage the tumor while keeping metabolism healthy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabergoline (a dopamine agonist drug)
What this could lead to: If successful, this trial could help doctors choose the best cabergoline dose to manage prolactinoma while minimizing negative effects on blood sugar.
What could go wrong: This is a small, early-phase trial (60 people) comparing different doses of an existing drug, not testing a new cure. Results may not apply to all patients, and cabergoline can cause side effects like nausea or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROLACTINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperprolactinemia prolactin deficiency, isolated prolactin-producing pituitary gland adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROLACTINOMA

Contacts and locations

Locations

University Hospital Basel, Dept. of Endocrinology, Metabolism & Diabetes
RECRUITING

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.